

ASX ANNOUNCEMENT

14 May 2026

Clarity receives \$9.8 million R&D tax incentive refund

Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that it has received a Research and Development (R&D) Tax Incentive refund of \$9,759,467, as part of the Australian Federal Government’s R&D Tax Incentive program. The refund recognises the significant eligible Australian R&D undertaken by Clarity in the radiopharmaceutical field in the financial year ended 30 June 2025.

The Australian Federal Government’s R&D tax incentive program encourages companies to engage and invest in R&D activities by providing a refundable tax offset of up to 48.5% of the eligible activities. The receipt of the \$9.8 million will provide additional funding to further the development of Clarity’s Targeted Copper Theranostic (TCT) platform of products for various cancer indications.

Clarity’s Executive Chairperson, Dr Alan Taylor, commented, “We are pleased to receive the RDTI with this significant amount reflecting our commitment to continuous investment into research and development. Clarity is built on a strong foundation of good Australian science, and our team works tirelessly to translate the benchtop research through high-quality clinical development and to the market with the ultimate goal of improving treatment outcomes for people with cancer.

“As we continue growing closer to commercialisation with our SAR-bisPSMA and SARTATE products, generating promising data in late-stage trials, we are appreciative of the non-dilutive funding that extends our cash runway and also enables Clarity to explore novel targets in indications with high unmet needs.”

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers.

www.claritypharmaceuticals.com

For more information, please contact:

Clarity Pharmaceuticals

Dr Alan Taylor

Executive Chairpersonataylor@claritypharm.com

Lisa Sadetskaya

Director, Corporate Communicationslisa@claritypharm.com

This announcement has been authorised for release by the Executive Chairperson.